Eleven Therapeutics Recognized as One of the 50 Most Promising Startups in Israel
May 11, 2023
The biotech company develops groundbreaking technology for programmable RNA drug development via AI and combinatorial chemistry
Source: https://www.calcalistech.com/ctechnews/article/hjtwkugx2
[CAMBRIDGE, UK and TEL AVIV, Israel] — Eleven Therapeutics, a biotechnology company leading the AI revolution in nucleic acid therapies, has been named among the “50 Most Promising Startups in Israel” by the leading business publication Calcalist.
This annual list, which recognizes the most promising companies in Israel’s startup ecosystem, features a diverse range of companies from various industries. Eleven Therapeutics was recognized for its groundbreaking work in the transformation of RNA drug development into a programmable process via combinatorial chemistry and artificial intelligence and is the only biotech company on the list.
Referencing the drop in overall venture capital investments in the market this year, Calcalist categorised this year’s list as comprised of “companies with a real impact model”.
“We are honoured to be recognized as one of the 50 most promising startups in Israel,” said Prof. Yaniv Erlich, CEO of Eleven Therapeutics. “Our team has been working tirelessly to develop and prove the groundbreaking technology behind Eleven’s therapeutics, and this recognition — and the fact that Eleven is the sole biotech company on this year’s list — is a testament to their dedication.”
Researchers at Eleven Therapeutics have been developing xRNA — mRNA molecules that are rationally designed to harbour chemical modifications in precise locations. To this end, the company has been building a high throughput platform, called TERA to decipher the Structure-Activity Relationship (SAR) of chemical modifications on xRNAs. The number of possible molecular compositions is staggeringly high, exceeding the number of grains of sand on earth. The platform solves this challenge by generating functional data about the activity profile of an unprecedented scale of xRNA molecules in parallel. In order to unlock the rules of SAR, the team is developing a robust deep learning framework. Ultimately, this proprietary, patent-protected, massively parallel bio-engineered screening platform will systematically identify the best combination of building block combinations for therapeutic candidates.
“We believe that our technology platform has the potential to transform nucleic acid therapeutics against some of the world’s most devastating diseases,” said Dr. Iris Grossman, Eleven’s Chief Therapeutics Officer. “It is thrilling to be recognized not only for our frontier-breaking scientific innovation, but for the contributions our company is making to Israel’s startup ecosystem.”
About Eleven Therapeutics
Eleven Therapeutics ushers in the next generation of mRNA therapeutics by combining artificial intelligence (AI), massively parallel functional assays, and combinatorial chemistry. Its flagship invention features a new modality, dubbed xRNA: a fully programmable mRNA molecule, rationally designed to harbour in specified locations chemical modifications that address delivery, durability, and efficacy challenges. To learn more, visit www.eleventx.com.
